Literature DB >> 22969876

Multidetector-computed tomography attenuation values between the tumor and aortic wall in response to induction therapy for esophageal cancer and its predictive value for aortic invasion.

Hironori Tsujimoto1, Takashi Ichikura, Satoshi Aiko, Yoshihisa Yaguchi, Isao Kumano, Risa Takahata, Yusuke Matsumoto, Kazumichi Yoshida, Satoshi Ono, Junji Yamamoto, Kazuo Hase.   

Abstract

The objective of this study was to evaluate the multidetector computed tomography (MDCT) attenuation value between the tumor and aorta in response to the induction therapy for esophageal cancer. In advanced esophageal cancer, the main reason for unresectability is the local invasion of the tumor into the aorta or trachea. Despite remarkable advances in diagnostic modalities, pre-operative assessment of pathological response and local tumor extent in esophageal cancer remains difficult. MDCT attenuation values between the tumor and aorta, and the contact angle of the tumor to the aorta (Picus' angle) were retrospectively evaluated in patients with esophageal cancer who underwent induction therapy in terms of predicting the pathological response, aortic invasion and prognosis of esophageal cancer. The induction therapy may increase the tumor-to-aorta distance and decrease the maximum tumor size and Picus' angle. When the tumor-to-aorta cut-off value was set at <1.3 mm, the accuracy of this distance for aortic invasion was 94.6%. In terms of this distance, 14 out of 19 patients with a tumor-to-aorta distance of <1.3 mm prior to the induction therapy had a distance of >1.3 mm following therapy and underwent curative resection. The assessment of the MDCT attenuation value between the esophageal tumor and the aorta is simple and objectively assesses the response to the induction therapy and aortic invasion in esophageal cancer. This method should be applied to predict the response to the induction therapy and to prevent unnecessary surgery in patients with tumors involving the aorta.

Entities:  

Year:  2011        PMID: 22969876      PMCID: PMC3438728          DOI: 10.3892/etm.2011.386

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  14 in total

Review 1.  Multimodality therapy for resectable cancer of the thoracic esophagus.

Authors:  John W C Entwistle; Melvyn Goldberg
Journal:  Ann Thorac Surg       Date:  2002-03       Impact factor: 4.330

Review 2.  Esophageal cancer.

Authors:  Peter C Enzinger; Robert J Mayer
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

3.  Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer.

Authors:  Jeongmin Choi; Sang Gyun Kim; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  Surg Endosc       Date:  2009-12-24       Impact factor: 4.584

4.  TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer.

Authors:  L H Sobin; I D Fleming
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

5.  Prognosis of esophageal cancers preoperatively staged to be locally invasive (T4) by endoscopic ultrasound (EUS): a multicenter retrospective cohort study.

Authors:  A Chak; M Canto; H Gerdes; C J Lightdale; R H Hawes; M J Wiersema; G Kallimanis; T L Tio; T W Rice; H W Boyce
Journal:  Gastrointest Endosc       Date:  1995-12       Impact factor: 9.427

6.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Authors:  Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

7.  Computed tomography in the staging of esophageal carcinoma.

Authors:  D Picus; D M Balfe; R E Koehler; C L Roper; J W Owen
Journal:  Radiology       Date:  1983-02       Impact factor: 11.105

8.  A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer.

Authors:  Bryan H Burmeister; Euan T Walpole; Nancy D'Arcy; Elizabeth A Burmeister; Sharon Cox; Damien B Thomson; Jennifer A Harvey; B Mark Smithers
Journal:  Invest New Drugs       Date:  2008-10-08       Impact factor: 3.850

Review 9.  Staging of oesophageal cancer.

Authors:  Stefan Diederich
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

10.  Staging work-up of patients with esophageal cancer.

Authors:  Leslie E Quint
Journal:  Cancer Imaging       Date:  2007-07-23       Impact factor: 3.909

View more
  1 in total

1.  Is 18F-FDG-PET useful for predicting R0 resection after induction therapy for initially unresectable locally advanced esophageal carcinoma?

Authors:  Keijiro Sugimura; Hiroshi Miyata; Masahiko Yano; Yoshitomo Yanagimoto; Moon Jeong Ho; Shogo Kobayashi; Hidenori Takahashi; Takeshi Omori; Masayuki Ohue; Masato Sakon
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.